Rhythm

FDA Grants Breakthrough Device Designation to Anumana’s ECG Pulmonary Hypertension Early Detection AI Algorithm

Developed in collaboration with Janssen and Mayo Clinic, this technology has the potential to aid physicians in earlier detection of pulmonary hypertension, a progressive, life-threatening disease CAMBRIDGE, Mass.–(BUSINESS WIRE)–Anumana, Inc., an AI-driven health technology company from nference, Inc., today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Device […]

First Patients Enrolled in IMPACT II Study to Evaluate Attune Medical’s ensoETM for Radiofrequency Ablation Procedures

Continued Research into Efficacy of ensoETM for RF Ablation Procedures Will Support Future Regulatory Efforts for Expanded Indications CHICAGO–(BUSINESS WIRE)–Attune Medical, a pioneering medical device company with a technology platform based on temperature management using the esophagus, announced today that the first patients have been enrolled in the Improving Oesophageal Protection During […]

Texas Cardiac Arrhythmia Institute at St. David’s Medical Center to host international conference on complex cardiac arrhythmias

EPLive 2022 is a two-day conference that draws the world’s top cardiac electrophysiology experts AUSTIN, Texas, May 20, 2022 /PRNewswire/ — On June 2 and 3, 2022, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center will host its sixth international symposium on complex arrhythmias, EPLive 2022. EPLive is an intensive, two-day […]

Keros Therapeutics Presents Results from a Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference

LEXINGTON, Mass., May 17, 2022 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced results from a preclinical […]

HUYABIO INTERNATIONAL ANNOUNCES COMPLETION OF HBI-3000 PHASE 1 TRIAL AND FDA APPROVAL TO PROCEED WITH DOSE ESCALATION IN PHASE 2

Phase 1 trial evaluated the pharmacokinetics and safety of HBI-3000 when dosed with thestrong CYP2D6 inhibitor, paroxetine SAN DIEGO, May 17, 2022 /PRNewswire/ — HUYABIO International, the leader in accelerating global development of China’s pharmaceutical innovations, today announced the successful completion of a Phase 1 drug-drug interaction clinical trial of HBI-3000, a novel drug for cardioversion […]

egnite, Inc. Expands into Cardiovascular Disease Supported by New Data on the State of Care for Patients with Atrial Fibrillation

Company to focus on improving the quality of care for all cardiovascular patients in the U.S. ALISO VIEJO, Calif.–(BUSINESS WIRE)–On the heels of its landmark valvular heart disease (VHD) prevalence abstract published in Journal of the American College of Cardiology (JACC), egnite, Inc. today announced that it has expanded the company’s focus […]

Pulse Technologies’ Electrode Surface Treatment Chosen for Cardiac Device

Pulse Technologies’ HSR™ electrode surface treatment is now part of Cardionomic’s Cardiac Pulmonary Nerve Stimulation (CPNS) System for treating heart failure. QUAKERTOWN, Pa., May 16, 2022 /PRNewswire/ — Pulse Technologies Inc. has announced that its proprietary Hierarchical Surface Restructuring (HSR™) technology is being utilized as part of Cardionomic’s Cardiac Pulmonary Nerve Stimulation […]

Acutus Medical completes enrollment in IDE trial with its AcQBlate® FORCE Sensing Ablation System

CARLSBAD, Calif., May 13, 2022 (GLOBE NEWSWIRE) — Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced successful completion of patient enrollment in the company’s AcQForce™ Flutter Investigational Device Exemption (IDE) clinical trial which enrolled 110 patients at […]